5-propynylarabinofuranosyluracil (netivudine)

01/01/1993 - "The plasma concentration profiles at these doses were in excess of IC50 values and support the use of once- or twice-daily regimens in future studies of 882C87 in herpes zoster."
03/01/1996 - "Multiple dose netivudine, a potent anti-varicella zoster virus agent, in healthy elderly volunteers and patients with shingles."
02/01/1995 - "6. 882C87 is a potential once daily treatment for shingles."
01/01/1993 - "Potentially therapeutic plasma concentrations are readily achieved in humans; the pharmacokinetics have been previously evaluated in healthy young and elderly (> 65 years) volunteers following single oral doses of 50-400 mg. Thirty immunocompetent patients with localised herpes zoster were treated with 882C87. "
01/01/1993 - "Preliminary pharmacokinetics and safety of 882C87 in patients with herpes zoster."

12/01/2010 - "By the individual genotype analysis, three polymorphisms (-574G/T, -882C/T, and -1516G/T) within TIM-3 gene were significantly associated with gastric cancer in the study population [ORs (95% CIs): 2.74 (1.21-6.20), 3.19 (1.29-7.91), and 2.03 (1.15-3.59); respectively]. "

09/01/2011 - "To find the relationship between the polymorphism of the Tim-3 gene mononucleotide site rs10515746 (-574G > T), rs4704853 (-882C > T), rs13170556, rs6555849 and the allergic rhinitis (AR) susceptibility in a population of Uigurs and Hans from Xinjiang Uigur Autonomous Region of China. "

05/01/1996 - "These findings suggest that netivudine dosage may need to be reduced in patients with severe renal failure, and confirm that formation of the 5 PU is independent of the elimination of netivudine from plasma."
05/01/1996 - "The pharmacokinetics of a single oral 200 mg dose of netivudine (1-(beta-D-arabinofuranosyl)-5-(1-propynyl)uracil), a nucleoside analogue under development for use in varicella zoster virus infections, were studied in 12 renal failure (RF) subjects (creatinine clearance 15 +/- 7 mL/min) and 12 age-matched healthy subjects with normal creatinine clearance. "

05/01/1996 - "The pharmacokinetics of a single oral 200 mg dose of netivudine (1-(beta-D-arabinofuranosyl)-5-(1-propynyl)uracil), a nucleoside analogue under development for use in varicella zoster virus infections, were studied in 12 renal failure (RF) subjects (creatinine clearance 15 +/- 7 mL/min) and 12 age-matched healthy subjects with normal creatinine clearance. "